PharmaTech 2024 Conference

Place: Online

Date: 14-15 November 2024
Language: English

Key poins:

  1. Next-Gen AI for Healthcare Transformation
  2. Clinical Trial Diversity & Digital Accessibility
  3. Patient-Centric Healthcare Technologies
  4. Automation in Biopharmaceutical Development
  5. Data Security & Access Controls
  6. Telemedicine & Remote Healthcare Empowerment
  7. Modern Pharmaceutical Quality Systems
  8. AI in Healthcare Revenue Management

Welcome to the PharmaTech 2024 Conference! Prepare for an enlightening journey into cutting-edge areas such as NextGen AI, diverse clinical trials, digital accessibility, automation, data security, telemedicine, patient empowerment, and modern pharmaceutical systems.

Get ready for an agenda that transcends boundaries, fostering knowledge exchange and setting the stage for groundbreaking advancements.

Agenda

Our speakers

Biocompatibility Specialist

Biocompatibility Specialist

Biocompatibility Specialist

R&D Engineer Medical Devices

Head of Material Development & Biocompatibility

The conference contains

10+ different topics

Exceptional networking opportunities

Panel discussion

Certificate of Attendance

Post-conference materials

Who should attend:

The PharmaTech 2024 Conference is crafted for participants across diverse industries, including pharmaceutical executives, biotechnology leaders, healthcare innovators, clinical research professionals, data sience and analytics teams, CROs, diagnostics, solution providers, and government institutions.

Our attendees comprise Chief Data Officers, VPs, GMs, Directors, Heads, and Managers specializing in key areas such as:

  • drug discovery
  • clinical trials
  • big data solutions
  • AI / machine learning
  • digital innovation
  • regulatory affairs
  • IT strategy
  • real-world data and evidence
  • R&D IT
  • translational informatics
  • data science
  • genomics
  • healthcare IT, and more

This comprehensive gathering ensures insightful discussions and valuable networking opportunities across various domains.

Featured Speaker Companies:

Benefits of attendance:

  • Meet new connections in groups or one-on-one
  • Further develop and strengthen your network
  • Expand your knowledge
  • Stay up to date
  • Grow your personal brand
  • Enjoy, create memories and have fun

About PharmaTech 2024 Conference:

PharmaTech 2024 Online Conference invites you to embark on a journey into the cutting-edge realms of healthcare innovation. Over two immersive days, delve into NextGen AI, clinical trial diversity, digital accessibility, automation, data security, telemedicine, patient empowerment, and modern pharmaceutical systems. This transformative event fosters collaborative ideation and drives groundbreaking advancements. Engage with industry luminaries, share insights, and shape the future of pharmaceutical innovation through thought-provoking panel discussions, interactive sessions, and engaging keynote speeches. Beyond exploration, the conference offers invaluable networking opportunities, enabling you to connect, forge partnerships, and build relationships that propel your career and impact. Whether you’re a seasoned professional, researcher, entrepreneur, or technology enthusiast, PharmaTech 2024 Online Conference promises to equip you with actionable strategies, insights, and connections to thrive in the dynamic landscape of modern healthcare.

What our clients say about our Events

Media Partners

Our Sponsors

REQUEST BROCHURE

PharmaTech 2024 Conference

Rose-Marie Jenvert

Rose-Marie Jenvert has over 20 years of experience within the medical device, pharma and biotechnology industry, and is currently working as Biocompatibility Specialist at Veranex, located in Lund Sweden. Rose-Marie is an experienced method developer of in vitro methods and holds a MSc in Molecular Biology and a PhD in Cell Biology. She has experience in performing biological evaluations of medical devices and has previously worked as study director for biocompatibility studies, setting up testing strategies and coordinating biological and chemical testing. She also has hands-on experience of testing different materials and medical devices.

Rose-Marie is actively working as an expert in ISO/TC194 WG8 with updating of the standards for skin sensitization and skin irritation (ISO 10993-10 and -23), and is also involved in the work of WG5, the standard for cytotoxicity.

Michael Burkard

Michael works as a Biocompatibility Specialist at Sonova AG, focusing on evaluating and implementing biocompatibility testing strategies for medical devices and materials. Furthermore, he has experience as a project manager in Product Stewardship, ensuring safety and regulatory compliance in the chemical sector. Since his Ph.D. in environmental toxicology, Michael consistently emphasized the development and application of innovative in vitro methods, such as the development of novel cell lines for toxicity screening. He will share practical insights and present case studies about his experience using in vitro sensitization methods for medical devices.

Jan Wirsching

Jan Wirsching has many years of experience in the medical device industry working in the field of biocompatibility and material compliance, and is currently working at Maquet Cardiopulmonary GmbH, a Getinge Company. Jan holds degrees in Molecular Medicine and Toxicology. He has experience in performing biological evaluations, toxicological risk assessments and material compliance evaluations for a wide range of devices, including combination products. Jan Wirsching is actively working as an expert in the development of a guideline on characterizing and assessing nanomaterials in medical devices and in vitro diagnostics (VDI 5709).

Theme: Complexity of Combination Products: Drug Device Interactions

– What are drug device interactions and how to investigate them?

– How do drug device interactions influence the biological risk assessment?

– Case Study: Biological risk assessment of a Heparin/Albumin-coated combination product

Klaudia Krzeszewska

Klaudia Krzeszewska, biomedical engineer by training, with special focus on biomaterials. During past 4 years in medical device industry in Regulatory Affairs and Research & Development, she worked with catheters, biodegradable stents and combination products. Interested in circular economy and sustainable approach to medical devices‘ development and manufacturing.

Ira Sharma Sankhayan

Ira has 18 yrs of experience in the industry. Having a bachelor in electronics and masters in microelectronics, she started her career as a DnD engineer. Since 2011, as a Global commodity role in GEHC, she stepped into the world of regulatory compliance for medical devices. Since, then she has been a part of more than 100 projects, leading the roles as a CTO, Head of QA RA, PRRC and Design transfer leader. Yallow life science started in September 2020, a consultancy firm, both with DnD and QA RA, where Ira Led the QA RA team and built it. Since then, the company has grown and has led many projects in combination. Presently She is the CEO of the company.

Fabian Kriegel

Fabian Kriegel is currently Head of Material Development and Biocompatibility at Carl Zeiss Meditec AG, where he leads a dynamic team focused on the development of biocompatible materials, particularly for ophthalmic applications. Together with his dedicated team, Fabian ensures the seamless implementation of testing strategies in accordance with international standards for safety and efficacy. His expertise also extends to guiding projects through the complex processes of international regulatory approval, facilitating the acceptance of medical devices on a global scale.

Prior to his current role, Fabian held positions such as GLP Study Director and Genetic Toxicology Laboratory Manager in the pharmaceutical industry. Academically, Fabian has contributed to various research areas such as nanomaterial toxicity, analytical chemistry and computational biology. In addition, he is recognized as a European Registered Toxicologist and an active member of various toxicology societies.

Join Our Event Alerts